Pharmacogenetic Panel Test: Medication Response, Gene Variants, and Results

A pharmacogenetic panel test examines several inherited genes at once to identify medication responses that may differ from the average. It can reveal slower or faster drug metabolism, reduced activation of a prodrug, a higher risk of a serious adverse reaction, or a likely need for a different starting dose. The result is not a universal list of medicines that will or will not work. Each finding applies only to particular gene–drug pairs, and its value depends on the quality of the laboratory method and the strength of the clinical guideline behind it. A panel can be ordered because a treatment decision is pending, or it can be performed preemptively so results are available for future prescriptions. The greatest benefit comes when actionable results are stored in the health record, checked whenever a relevant medicine is prescribed, and interpreted alongside age, kidney and liver function, other drugs, diagnosis, and treatment goals.

• A panel tests multiple medication-response genes from one DNA sample, but every reported gene is not equally actionable.
• Results usually remain valid for life, although the clinical interpretation and prescribing guidelines can change.
• Common actionable genes include CYP2C19, CYP2D6, DPYD, TPMT, NUDT15, SLCO1B1, CYP2C9, VKORC1, and selected HLA genes.
• No fasting is normally needed, and blood, saliva, or a cheek swab may be used.
• A “normal” result does not guarantee benefit or safety, because genetics is only one source of treatment variability.
• Do not change medication from a color-coded report alone; match the exact gene, phenotype, drug, and current guideline.

Table of Contents

• What a panel can answer
• Genes and medications commonly included
• Reactive versus preemptive testing
• Choosing a reliable panel
• Sample collection and turnaround
• Interpreting the report
• Putting results into clinical use
• Limitations, cost, privacy, and follow-up

What a panel can answer

A pharmacogenetic panel asks whether inherited DNA variants are likely to alter the handling or effects of specific medicines. It is broader than a single-gene test and narrower than whole-exome or whole-genome sequencing. The laboratory usually targets selected variants, star alleles, copy-number changes, or HLA types with known medication associations.

The panel may identify four broad kinds of information:

• Drug metabolism: A person may break down a medicine more slowly or quickly than expected. CYP2D6, CYP2C19, CYP2C9, CYP3A5, and CYP2B6 are common metabolism genes.
• Prodrug activation: Some medicines need an enzyme to become active. Examples include clopidogrel activation through CYP2C19 and codeine activation through CYP2D6.
• Drug transport or disposition: Transporter variants can change how much drug reaches the blood or liver. SLCO1B1 is relevant to statin exposure and muscle toxicity risk.
• Immune-mediated adverse reactions: Certain HLA variants strongly predict severe hypersensitivity with particular drugs, such as HLA-B57:01 with abacavir and HLA-B15:02 with carbamazepine in at-risk populations.

A panel does not diagnose the condition being treated. It does not show the current drug concentration, prove that a side effect came from a medicine, or predict adherence. It also cannot replace kidney tests, liver tests, blood counts, electrocardiograms, therapeutic drug monitoring, or clinical follow-up when those are required.

Pharmacogenetics is most useful when a report connects a genotype to a defined phenotype and then to a medication-specific recommendation. A general statement such as “reduced metabolism” is incomplete unless it identifies the enzyme and drug. Reduced metabolism can increase exposure to an active medicine but decrease benefit from a prodrug. The same phenotype can therefore lead to opposite clinical effects.

A panel also differs from a general genetic panel test for disease risk. Pharmacogenetic panels usually analyze germline variants for prescribing decisions rather than searching for inherited disease-causing mutations. Incidental disease-risk findings are uncommon on a tightly designed panel, but the consent process should explain whether any could be reported.

The result should be viewed as a reusable prescribing resource. Because inherited DNA usually stays the same, the raw genotype can remain relevant for decades. The medical meaning may change as new evidence appears, variant definitions are revised, and professional guidelines are updated. Long-term usefulness therefore depends on access to reinterpretation, not only the original test.

Genes and medications commonly included

Panel content varies widely. Some tests include a dozen well-established genes, while others advertise dozens or hundreds of genes with uneven evidence. A concise panel with strong coverage can be more clinically useful than a large panel filled with associations that have no prescribing recommendation.

Gene or gene group	Example medicines	Possible clinical use
CYP2C19	Clopidogrel, some proton pump inhibitors, selected antidepressants, voriconazole	Choose an alternative, alter dose, or adjust monitoring for certain metabolizer phenotypes
CYP2D6	Codeine, tramadol, atomoxetine, selected antidepressants and antipsychotics	Avoid selected prodrugs in poor or ultrarapid metabolizers; modify dose for some active drugs
DPYD	Fluorouracil and capecitabine	Reduce starting dose or avoid treatment in patients with reduced or absent DPD activity
TPMT and NUDT15	Azathioprine, mercaptopurine, thioguanine	Lower initial dose or use an alternative when myelosuppression risk is high
SLCO1B1, ABCG2, CYP2C9	Selected statins	Choose a statin or dose with lower exposure and muscle-toxicity risk
CYP2C9, VKORC1, CYP4F2	Warfarin	Inform initial dose estimation together with clinical factors and INR monitoring
CYP3A5	Tacrolimus	Guide initial dosing while continuing trough concentration monitoring
HLA-B and HLA-A alleles	Abacavir, allopurinol, carbamazepine, oxcarbazepine	Avoid a drug when a validated high-risk immune allele is present

The strength of the recommendation differs across these examples. Some gene–drug pairs can prevent life-threatening toxicity and are widely accepted. Others mainly explain pharmacokinetic differences, and outcome evidence may be limited. A good report labels the evidence level instead of placing all results in the same “use with caution” category.

Panel design must also account for technically difficult genes. CYP2D6 has deletions, duplications, hybrid genes, and many alleles; testing only a few single-nucleotide variants can misclassify phenotype. HLA typing requires methods that accurately identify the relevant allele. DPYD panels often test several established decreased-function variants, but targeted testing cannot detect every rare cause of DPD deficiency. The report should state what was and was not assessed.

Ancestry affects allele frequencies but does not define an individual’s genotype. Some variants are more common in particular populations, and a panel built around variants found mainly in European ancestry may have lower sensitivity in other groups. Laboratories should use diverse reference data and explain residual risk after a negative result.

For an individual drug question, a focused test may be preferable. Examples include a CYP2C19 test for clopidogrel response or a TPMT test before thiopurine treatment. A panel becomes more attractive when several actionable medicines are likely over time or when one sample can answer multiple immediate questions.

Reactive versus preemptive testing

Reactive testing is ordered for a current problem. A clinician may request DPYD testing before fluoropyrimidine chemotherapy, HLA-B*57:01 before abacavir, or CYP2C19 after a cardiovascular event in a person taking clopidogrel. The result has a defined use, so interpretation is relatively direct.

Preemptive testing analyzes a panel before every result is needed. Findings are stored and retrieved whenever a relevant drug is considered. This approach avoids waiting for a new test during an urgent prescription and makes one DNA sample useful across specialties. It is most effective when the health system has clinical decision support that alerts the prescriber only when a result changes care.

A large European implementation study tested a 12-gene panel across several health systems and found fewer clinically relevant adverse drug reactions when prescribing followed genotype-guided recommendations. The result supports the potential of panel-based testing, but it does not mean every commercial panel or every gene provides the same benefit. The study used a defined panel, established recommendations, trained clinicians, and a structured medication-safety process.

Reactive testing may be more efficient when a person is unlikely to receive multiple affected drugs or when resources are limited. Preemptive testing may offer more value for people with polypharmacy, chronic illness, repeated treatment changes, transplantation, cancer care, or frequent contact with several prescribers. The best strategy depends on the health system, turnaround time, local formulary, and ability to maintain results over time.

The decision should consider whether testing will change management. Questions to ask include:

• Is a medication with an actionable gene association being considered?
• Would the result change the drug, dose, timing, or monitoring plan?
• Is the result needed before treatment starts?
• Is a previous result already available?
• Does the laboratory cover the variants needed for this patient and drug?
• Is a clinician or pharmacist available to interpret the report?
• Will future prescribers be able to find and use the result?

Testing after a side effect may clarify a contributing factor, but it cannot prove causation. For example, CYP2C19 poor metabolism may increase exposure to a selected antidepressant, yet the symptom may also reflect dose, interactions, illness, or another medicine. The clinical history remains essential.

A preemptive result should not be used to avoid effective therapy without a guideline-supported reason. Many people carry at least one actionable variant, but that does not mean they are broadly “medication sensitive.” Each result becomes relevant only when paired with the corresponding drug.

Choosing a reliable panel

A reliable panel begins with the clinical question and ends with transparent reporting. Marketing language such as “personalized medication blueprint” or “find the perfect drug” should prompt caution. No current panel can rank every medication for every condition with certainty.

Important laboratory features include:

• appropriate clinical laboratory accreditation and quality controls;
• clear identification of genes, alleles, variants, and copy-number methods;
• validated detection of structural variants when relevant;
• an explanation of phenotype translation rules;
• current, named prescribing guidelines;
• evidence grading for each gene–drug pair;
• limitations by ancestry, rare variants, and assay coverage;
• policies for amended reports and reinterpretation;
• access to a laboratory professional for complex questions.

Panels can use targeted genotyping, sequencing, or a combination. Targeted genotyping is efficient for known variants but misses changes outside the selected list. Sequencing can detect more variants but may identify changes with uncertain function and still may not resolve complex structural variation. More comprehensive technology does not remove the need for careful interpretation.

Results should use standardized terminology. Star-allele diplotypes such as CYP2C19 1/2 or CYP2D6 4/4 are often translated into phenotypes such as intermediate or poor metabolizer. For transporter genes, reports may use normal, decreased, or poor function. HLA results are typically positive or negative for a named allele. The report should never rely only on proprietary red, yellow, and green bins.

Drug lists on the report need context. A green category may mean “no gene-based change is recommended,” not “best medicine.” A red category may mean “use an alternative,” “reduce the dose,” “increase the dose,” or “monitor more closely.” Those are different actions. The prescriber needs the underlying recommendation.

Panel selection should not be based solely on the number of medications displayed. Some reports include drugs because the label mentions a gene even when no action is recommended. Others mix validated pharmacogenetic guidance with preliminary associations involving drug targets, treatment response, or disease risk. The test order should separate clinical-grade findings from research-level content.

A broad panel is a form of medication-response genetic testing, so informed consent should address expected benefits, limitations, possible secondary findings, data storage, and who will receive the report.

Sample collection and turnaround

Panel testing usually requires a cheek swab, saliva sample, or small blood sample. Fasting is not necessary. Medications can generally be taken as prescribed because they do not alter germline DNA. The ordering clinician still needs an accurate medication list because inhibitors, inducers, organ dysfunction, and other clinical factors affect how the genotype is expressed in practice.

Cheek and saliva collection must follow instructions closely. Eating, drinking, smoking, chewing gum, or brushing teeth shortly before collection can reduce sample quality, depending on the kit. A blood sample may be preferred when saliva production is limited, a prior oral sample failed, or the laboratory’s validated workflow uses blood.

Turnaround commonly ranges from several days to a few weeks. Urgent gene-specific testing may be faster in specialized centers. Before ordering, confirm whether the result will arrive in time to influence treatment. Starting a high-risk medicine while waiting may require a temporary alternative or intensified monitoring.

The laboratory workflow typically includes DNA extraction, variant detection, quality review, allele assignment, phenotype prediction, and report generation. A failure at any stage may lead to recollection or an indeterminate result. “No call” is not the same as a normal genotype.

Insurance coverage depends on the indication, plan, laboratory, and local policy. A panel may be covered when tied to a specific high-risk medicine but not when ordered broadly for future use. Patients can ask for the billing code, prior-authorization status, expected self-pay price, and whether interpretation services are included.

The result should be delivered in a durable format. A portable report or medication-passport summary can help when care occurs across multiple systems, but the complete laboratory report should remain available. A summary without the genotype, method, date, and limitations may be insufficient for future reinterpretation.

Interpreting the report

A panel report is best read one drug at a time. Begin with the active medication list or proposed prescription, then locate the corresponding gene and phenotype. Do not start by scanning for red boxes, because many highlighted findings may be irrelevant to current treatment.

A practical reading sequence is:

1. Confirm identity and sample details. Check the patient name, collection date, specimen, and laboratory.
2. Find the relevant drug. Identify whether the medicine is directly covered by an established guideline.
3. Read the genotype and phenotype. Note the allele combination and the predicted functional category.
4. Check assay coverage. Confirm whether deletions, duplications, HLA alleles, or rare variants were assessed when needed.
5. Read the exact recommendation. Determine whether it calls for avoidance, dose adjustment, a different drug, or additional monitoring.
6. Review clinical modifiers. Consider age, ancestry, organ function, pregnancy, indication, interactions, and prior response.
7. Document the action. Record what changed and why, or why no change was made.

Phenoconversion is an important source of mismatch between genotype and current function. A genetically normal CYP2D6 metabolizer taking a strong CYP2D6 inhibitor can function more like a poor metabolizer. Severe inflammation and organ disease can also alter enzyme activity. A panel is therefore not a substitute for medication reconciliation.

A negative result has limits. It may mean that no tested actionable variant was found, not that every pharmacogene is normal. Targeted panels can miss rare variants, and some detected variants cannot yet be assigned a function. “Indeterminate metabolizer” or “uncertain function” should lead to clarification rather than a guessed recommendation.

Conflicting sources require professional review. The FDA label, FDA association tables, CPIC, the Dutch Pharmacogenetics Working Group, and specialty organizations may differ in scope or wording. These differences do not always indicate that one is wrong; they may reflect different evidence thresholds and purposes. The report should identify the source and date used.

Results can also be outdated by changes in allele-function assignment. A diplotype originally labeled normal may later be classified differently. Reinterpretation is especially important before a high-risk medicine when the original report is old, the laboratory has issued an amendment, or the underlying variant call is incomplete.

Putting results into clinical use

The result creates value only when it changes a prescribing process. A paper report placed in a drawer is easily forgotten. The genotype and phenotype should be entered into the electronic health record in a structured form when possible, with the original report attached and medication-specific alerts available.

Clinical decision support works best when it is selective. An alert should appear when a prescriber orders a relevant medicine and should state the phenotype, risk, and recommended alternative or dose. Excessive low-value alerts cause fatigue and may reduce attention to the most important warnings.

Pharmacists often play a central role by reconciling medications, identifying interactions, checking guideline updates, and explaining options to patients and prescribers. A genetics professional may be helpful when results contain uncertain alleles, complex CYP2D6 structures, or implications beyond medication response.

Examples of appropriate use include:

• choosing an alternative antiplatelet drug for a CYP2C19 poor metabolizer when rapid, reliable platelet inhibition is needed;
• reducing a thiopurine starting dose for reduced TPMT or NUDT15 function while continuing blood-count monitoring;
• avoiding a high-risk drug when a strongly associated HLA allele is present;
• selecting a statin and dose with lower muscle-toxicity risk for a person with reduced SLCO1B1 function;
• increasing the initial tacrolimus dose for a CYP3A5 expresser while using trough concentrations to adjust ongoing therapy.

The result should not be applied outside its evidence. A CYP2D6 poor-metabolizer result may affect codeine, atomoxetine, and some antidepressants in different ways. It should not lead to avoidance of every CYP2D6 substrate. Recommendations depend on whether the drug is active, requires activation, has other metabolic pathways, and has a wide or narrow therapeutic window.

Patients benefit from a concise explanation: “This result matters for these named medicines and may change the starting choice or dose. It does not mean other medicines are unsafe.” A current medication list and the full report should be shared with new clinicians, dentists, pharmacists, and hospitals when relevant.

Limitations, cost, privacy, and follow-up

Pharmacogenetic panels cannot account for all causes of variable treatment response. Drug interactions, kidney and liver function, age, body size, disease severity, adherence, smoking, diet, and concurrent illness may outweigh a genetic effect. Some medicines have no validated genetic predictor, and many reported associations have not shown improved clinical outcomes.

Technical limitations include incomplete variant coverage, uncertain alleles, allele dropout, complex structural variation, and phenotype translation errors. These risks are reduced by validated methods and quality review but never disappear completely. Results from a consumer ancestry file should not be treated as equivalent to a clinical pharmacogenetic test.

Equity also matters. Evidence and test design have historically overrepresented people of European ancestry. Panels that omit variants found in other populations can provide false reassurance or less accurate phenotype assignments. Laboratories should disclose coverage, and clinicians should avoid using race as a substitute for genotype.

Privacy protections depend on jurisdiction, insurer, employer, and the way data are stored. Patients should ask whether samples are retained, whether de-identified data may be used for research, who can access results, and how deletion requests are handled. Pharmacogenetic results usually have less direct disease-risk meaning than diagnostic genetic tests, but they remain personal genetic information.

Follow-up should include a review of actionable findings, medication reconciliation, and a plan for future access. Ask the ordering clinician:

• Which results affect a medicine I take now?
• Which findings are supported by a prescribing guideline?
• Does the panel include copy-number and structural-variant testing where needed?
• Could any current drug inhibit or induce the relevant enzyme?
• Should the result be added to allergy or medication-alert fields?
• How will updated interpretations reach me?
• Is confirmatory testing needed before a high-risk decision?

Do not stop, start, or alter a prescription solely from the report. Abrupt changes can cause withdrawal, relapse, clotting, rejection, seizures, or other harm depending on the medication. Urgent symptoms should be managed clinically rather than waiting for genetic interpretation.

A well-designed panel can reduce avoidable adverse reactions and shorten trial-and-error prescribing, especially when it covers established gene–drug pairs and is embedded in ongoing care. Its usefulness is not measured by how many genes it tests, but by whether each result can be translated into a clear, evidence-based action at the moment a medicine is chosen.

References

• A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study 2023 (Clinical Study)
• Pharmacogenetic Panel Testing: A Review of Current Practice and Potential for Clinical Implementation 2025 (Review)
• Clinical Pharmacogenetic Testing and Application: 2024 Updated Guidelines by the Korean Society for Laboratory Medicine 2025 (Guideline)
• Pharmacogenetic Implementation Studies—Lessons Learned From the PREPARE Study 2025 (Review)
• Table of Pharmacogenomic Biomarkers in Drug Labeling 2026 (Official Resource)
• Table of Pharmacogenetic Associations 2022 (Official Resource)

Disclaimer

This article provides general education and is not a substitute for medical advice, laboratory consultation, or current prescribing guidance. A qualified clinician should interpret each result for the exact medicine, indication, health conditions, and drug interactions. Do not change a prescription based only on a panel report without speaking with the prescriber.